The new Omni 30° hysteroscope, Omni Lok cervical seal and Omni 5 French Seal provide greater flexibility to support doctors in diagnosing and treating patients

Marlborough, Massachusetts, September 30, 2021--(BUSINESS WIRE)--Hologic, Inc. (NASDAQ: HOLX), a global leader in women’s health, has launched its extended Omni® suite, This is a comprehensive gynecological surgery product designed to optimize diagnosis and surgical hysteroscopy in Europe, Africa and the Middle East (EMEA). The product now includes the multifunctional Omni 30° hysteroscope, Omni Lok cervical seal and Omni 5 French seal, which complement the company's existing GYN surgical solution portfolio and expand the doctor's choice.

The Omni Hysteroscopy product portfolio provides improved diagnostic and surgical versatility through three interchangeable sheaths, ranging from 3.7 to 6 mm, with 0° or new 30° field of view options. The long working length of 200 mm further supports the adjustment procedure according to the patient's anatomy. This interchangeable sheath system achieves "observation and treatment" applications by quickly switching from diagnostic hysteroscopy to surgical hysteroscopy, without the need for disinfection even in an outpatient setting. Therefore, Omni hysteroscope with high-quality HD rod lens is designed to provide the best hysteroscopy experience.

The Omni™ Lok cervical seal and Omni 5 French sealing cap have been added to Hologic's product portfolio to improve the efficiency of the operation. Omni Lok seals are first-class products designed to help maintain uterine dilation and improve operating room (OR) efficiency by reducing fluid leakage during hysteroscopic surgery by an average of 94%. 1,2 Compatible with MyoSure® and Omni hysteroscope. When using 5 French tools, the Omni 5 French sealing cap can also reduce leakage and back splash by more than 75%. 3

"The option of'seeing a doctor' is becoming more and more common in Europe. People are becoming more aware of the benefits of transferring these types of surgeries to an outpatient setting, and this has been further emphasized during the pandemic. Gynecologists need Having access to a wider range of products allows them to quickly adapt to the requirements of each patient," said Tanja Brycker, vice president of strategic development for BSH and Surgery International. "Hologic has conducted extensive consultations with our customers, and the latest Omni hysteroscope product suite was developed based on their feedback. This is especially true for the Omni 30° hysteroscope, which clearly demonstrates our continued commitment to meeting customer needs We expect the Omni 30° will soon become the device of choice for outpatient clinics of gynecologists in Europe, the Middle East and Africa."

Managing fluid loss is a key element of hysteroscopy, as reduced fluid on the floor and operating table can improve doctors’ estimates of fluid loss and reduce cleaning and operating room turnaround time. This in turn can help doctors arrange more patients and improve work efficiency. 1,2

Hologic's complete product suite includes Omni 30° and 0° hysteroscopes, Omni Lok cervical seals and Omni 5 French Seal. Omni Suite is designed to increase the utilization of Hologic's broader GYN surgical product portfolio, including MyoSure® tissue removal system and Fluent® fluid management system.

For more information about these products and Hologic's complete hysteroscopic surgery portfolio, please visit Gynsurgicalsolutions.co.uk.

Hologic, Inc. is an innovative medical technology company focused on improving women's health and well-being through early detection and treatment. For more information about Hologic, please visit www.hologic.com.

Hologic, Fluent, MyoSure, NovaSure, Omni and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

The Omni® 0° and 30° hysteroscopes are designed to provide observation of the cervical canal and uterine cavity in order to perform diagnostic and surgical procedures. Omni 0° and 30° hysteroscopy is not suitable for patients with acute pelvic inflammatory disease or the following conditions: inability to dilate the uterus, cervical stenosis, cervical/vaginal infection, uterine bleeding or menstruation, cervical invasive cancer, recent uterine perforation, medical contraindications Symptoms or intolerance to anesthesia.

The Omni® Lok cervical seal is used during hysteroscopic surgery to minimize leakage of liquid swelling media from the cervix. The Omni Lok cervical seal should not be used in patients with contraindications to hysteroscopy.

This press release may contain forward-looking information involving risks and uncertainties, including statements regarding the use of Hologic products. There is no guarantee that these products will achieve the benefits described in this article, or that such benefits will be replicated to individual patients in any particular way, because the actual effects of using these products can only be determined on a case-by-case basis. In addition, there is no guarantee that these products will be commercially successful or reach any expected sales level. Hologic expressly disclaims any obligation or commitment to publicly release any updates or amendments to any such statements provided here to reflect any expected changes or any changes in events, conditions or circumstances on which any such data or statements are based.

This information is not intended as a product solicitation or promotion that prohibits such activities. For specific information about which products are available for sale in a specific country, please contact your local Hologic sales representative or write to womenshealth@hologic.com.

1 Hologic data archive. VAR-08420. Physician questionnaire behind the video introduction device; N=15 2 Hologic data archive, VER-09159, bench test using uterine model; N=22 3 Hologic data archive. VER-10319

View the source version on businesswire.com: https://www.businesswire.com/news/home/20210930005269/en/

Media contact: Jane Mazur +1 508.263.8764 (direct) +1 585.355.5978 (mobile) jane.mazur@hologic.com

Investor Contact: Michael Watts +1 858.410.8588 michael.watts@hologic.com

These growth stocks are not household names. However.

Pfizer agreed to acquire Arena Pharmaceuticals, a US biotechnology company, for approximately US$6.7 billion.

Buffett's right-hand man just sounded the bubble alarm. Maybe it's time to heed his warning.

These companies not only provide high-yield expenditures, but also have a good track record of increasing expenditures on a regular basis.

These three companies involve different risks, but in the long run, each company can enhance your investment portfolio.

Intel (NASDAQ: INTC) initially appeared to be an attractive investment for value-oriented income investors. Since Pat Gelsinger took over as the new CEO in February, Intel's internal sentiment has also improved. In the past 12 months, Intel insiders bought almost twice as many stocks as sold stocks. Intel's low valuation and high yield may limit its downside potential, but four red flags may also prevent it from outperforming the market.

Nvidia's (NASDAQ: NVDA) share price has risen 140% so far this year, which is on top of the staggering 750% increase in the past three years. Buying popular technology stocks like Nvidia can be tricky. On the one hand, in the long run, NVIDIA has obvious opportunities to increase revenue and expand profits. Before deciding to buy Nvidia at these high points, the following most important factors need to be considered.

The greater the premium of the stock price relative to its long-term moving average, the greater the enthusiasm of investors for its upward prospects. But when expectations become too enthusiastic, interesting things happen to its graphs.

Solana suffered a high-profile distributed denial of service attack.

The Biden administration is working hard to promote electric vehicles (EV). From the US$7.5 billion allocated in the “Rebuild Better” bill to expand and increase the charging station network, to political pressure on automakers to commit to increased production, the goal is to convert 40% of car sales to electric by the end of the decade Automobiles, it is very obvious that under Biden's leadership, the government is willing to promote major changes in the automobile industry. For investors, this political environment makes

The market is satisfied with the prospect of the Fed raising interest rates. Here are the headlines from Monday, December 13, 2021, and the content to watch in the market.

As far as the market is concerned, in the past 20 years, many major events have had a considerable impact on stock performance. The good news for shareholders is that the days when Amazon created higher revenue without profits are long gone.

A group of insurance companies are issuing cash after hoarding $5 billion in excess funds.

Did you know that Alibaba is also one of the top advertising, gaming and smart speaker companies in China?

The U.S. Bureau of Labor Statistics recently updated the inflation rate for November 2021, stating that the average price has risen by 6.8% in the past 12 months-if you keep the score, this is the highest level since 1982. The three contributors at Fool.com believe that Applied Materials (NASDAQ: AMAT), IBM (NYSE: IBM) and Micron Technology (NASDAQ: MU) can easily Beyond inflation, it's worth watching now. Nicholas Rossolillo (Applied Materials): Supply chain issues continue to cause severe damage to certain industries. There are many excellent semiconductor stocks there, but for investors who want to have wider exposure to the entire industry, I like Applied Materials.

The company is adding 15 billion U.S. dollars to its stock repurchase program, bringing the total authorization to approximately 15.2 billion U.S. dollars.

Our appeal from Stifel that day believes that the Fed is working hard to create a bubble of the century. This is what happened before.

This year, the two companies are developing in opposite directions, but in the long run, both companies are in an advantageous position.

The market has become hostile to expensive growth stocks, which may be bad news for Cloudflare.

Yuan platform (NASDAQ: FB), formerly known as Facebook, has attracted a lot of attention recently, mainly due to the reason for the name change. The company emphasized that it will actively invest to become the leader of Metaverse. On the other hand, some investors worry that the meta-platform may allocate time and financial resources to projects with uncertain results. Meta Platforms' business benefits from its family of social media applications, including Facebook, Instagram and WhatsApp.